Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

USA - NASDAQ:PYXS - US7473241013 - Common Stock

1.86 USD
-0.01 (-0.53%)
Last: 9/11/2025, 8:07:22 PM
1.8407 USD
-0.02 (-1.04%)
Pre-Market: 9/12/2025, 8:09:35 AM
Fundamental Rating

2

Overall PYXS gets a fundamental rating of 2 out of 10. We evaluated PYXS against 541 industry peers in the Biotechnology industry. The financial health of PYXS is average, but there are quite some concerns on its profitability. PYXS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PYXS had negative earnings in the past year.
PYXS had a negative operating cash flow in the past year.
PYXS had negative earnings in each of the past 5 years.
PYXS had a negative operating cash flow in each of the past 5 years.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PYXS has a Return On Assets of -78.14%. This is in the lower half of the industry: PYXS underperforms 66.36% of its industry peers.
The Return On Equity of PYXS (-109.86%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

PYXS has a better Gross Margin (555.71%) than 100.00% of its industry peers.
PYXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 555.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
PYXS has more shares outstanding than it did 1 year ago.
PYXS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PYXS is higher compared to a year ago.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PYXS has an Altman-Z score of -4.10. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PYXS (-4.10) is comparable to the rest of the industry.
PYXS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, PYXS is in line with its industry, outperforming 49.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.1
ROIC/WACCN/A
WACC9.58%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 5.65 indicates that PYXS has no problem at all paying its short term obligations.
PYXS has a Current ratio of 5.65. This is in the better half of the industry: PYXS outperforms 60.44% of its industry peers.
PYXS has a Quick Ratio of 5.65. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.65, PYXS is doing good in the industry, outperforming 60.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 5.65
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for PYXS have decreased by -0.81% in the last year.
PYXS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -82.53%.
EPS 1Y (TTM)-0.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.45%
Revenue 1Y (TTM)-82.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.10% on average over the next years.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 39.00% on average per year.
EPS Next Y-39.94%
EPS Next 2Y-11.52%
EPS Next 3Y-9.61%
EPS Next 5Y3.1%
Revenue Next Year-79.35%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.93%
Revenue Next 5Y39%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as PYXS's earnings are expected to decrease with -9.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.52%
EPS Next 3Y-9.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PYXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (9/11/2025, 8:07:22 PM)

Premarket: 1.8407 -0.02 (-1.04%)

1.86

-0.01 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners40.18%
Inst Owner Change-9.03%
Ins Owners5.7%
Ins Owner Change0%
Market Cap115.36M
Analysts84.62
Price Target6.32 (239.78%)
Short Float %10.59%
Short Ratio9.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.17%
Min EPS beat(2)-16.71%
Max EPS beat(2)16.37%
EPS beat(4)2
Avg EPS beat(4)3.97%
Min EPS beat(4)-16.71%
Max EPS beat(4)25.73%
EPS beat(8)5
Avg EPS beat(8)15.93%
EPS beat(12)7
Avg EPS beat(12)16.36%
EPS beat(16)7
Avg EPS beat(16)-119.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.89%
EPS NQ rev (1m)3.23%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)5.33%
EPS NY rev (3m)-13.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.91
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.05
BVpS1.41
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 555.71%
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 5.65
Altman-Z -4.1
F-Score2
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.45%
EPS Next Y-39.94%
EPS Next 2Y-11.52%
EPS Next 3Y-9.61%
EPS Next 5Y3.1%
Revenue 1Y (TTM)-82.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-79.35%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.93%
Revenue Next 5Y39%
EBIT growth 1Y-24.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.73%
OCF growth 3YN/A
OCF growth 5YN/A